Neues beim Schlaganfall – Teil 1: Akuttherapie

Diese Übersichtsarbeit referiert aktuelle Studien zur Klinik und Therapie des Schlaganfalls. Die Autoren haben die wichtigsten Arbeiten aus den 4782 Publikationen im Zeitraum zwischen Herbst 2019 und Oktober 2020 ausgewählt. Die neuen Daten beschäftigen sich mit dem Zeitfenster für die Thrombolyse und der Organisation der Thrombektomie beim akuten Schlaganfall sowie der Frage, ob die Thrombektomie mit oder ohne zusätzliche Thrombolyse durchgeführt werden soll. Im 2. Teil des Beitrags wird dann die Schlaganfallprophylaxe dargestellt [1].

• Literatur

• 1 Diener H-C, Endres M, Fiehler J. et al. Neues beim Schlaganfall – Teil 2: Prävention. Neurol Up2date 2021; 4: 51-66
• 2 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
• 3 Hacke W, Kaste M, Bluhmki E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329
• 4 Emberson J, Lees KR, Lyden P. et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929-1935
• 5 Lees KR, Emberson J, Blackwell L. et al. Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. Stroke 2016; 47: 2373-2379
• 6 Goyal M, Menon BK, van Zwam WH. et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387: 1723-1731
• 7 Thomalla G, Cheng B, Ebinger M. et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011; 10: 978-986
• 8 Thijs VN, Adami A, Neumann-Haefelin T. et al. Clinical and radiological correlates of reduced cerebral blood flow measured using magnetic resonance imaging. Arch Neurol 2002; 59: 233-238
• 9 Lansberg MG, Christensen S, Kemp S. et al. Computed tomographic perfusion to Predict Response to Recanalization in ischemic stroke. Ann Neurol 2017; 81: 849-856
• 10 Thomalla G, Simonsen CZ, Boutitie F. et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med 2018; 379: 611-622
• 11 Barow E, Boutitie F, Cheng B. et al. Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial. JAMA Neurol 2019; 76: 641-649
• 12 Ma H, Campbell BCV, Parsons MW. et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med 2019; 380: 1795-1803
• 13 Campbell BCV, Ma H, Ringleb PA. et al. Extending thrombolysis to 4.5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet 2019; 394: 139-147
• 14 Ringleb P, Bendszus M, Bluhmki E. et al. Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. Int J Stroke 2019; 14: 483-490
• 15 Davis SM, Donnan GA, Parsons MW. et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309
• 16 Nogueira RG, Jadhav AP, Haussen DC. et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018; 378: 11-21
• 17 Albers GW, Marks MP, Kemp S. et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018; 378: 708-718
• 18 Fiehler J. Direkt in ein neurovaskuläres Zentrum oder „drip and ship“?. Radiologe 2019; 59: 610-615
• 19 Turc G, Bhogal P, Fischer U. et al. European Stroke Organisation (ESO)- European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg 2019; 11: 535-538
• 20 McTaggart RA, Moldovan K, Oliver LA. et al. Door-in-door-out time at primary stroke centers may predict outcome for emergent large vessel occlusion patients. Stroke 2018; 49: 2969-2974
• 21 Ciccone A, Berge E, Fischer U. Systematic review of organizational models for intra-arterial treatment of acute ischemic stroke. Int J Stroke 2019; 14: 12-22
• 22 Fuentes B, Alonso de Lecinana M, Ximenez-Carrillo A. et al. Futile interhospital transfer for endovascular treatment in acute ischemic stroke: The Madrid Stroke Network Experience. Stroke 2015; 46: 2156-2161
• 23 Froehler MT, Saver JL, Zaidat OO. et al. Interhospital transfer before thrombectomy is associated with delayed treatment and worse outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke). Circulation 2017; 136: 2311-2321
• 24 Gerschenfeld G, Muresan IP, Blanc R. et al. Two paradigms for endovascular thrombectomy after intravenous thrombolysis for acute ischemic stroke. JAMA Neurol 2017; 74: 549-556
• 25 Rinaldo L, Brinjikji W, McCutcheon BA. et al. Hospital transfer associated with increased mortality after endovascular revascularization for acute ischemic stroke. J Neurointerv Surg 2017; 9: 1166-1172
• 26 Ismail M, Armoiry X, Tau N. et al. Mothership versus drip and ship for thrombectomy in patients who had an acute stroke: a systematic review and meta-analysis. J Neurointerv Surg 2019; 11: 14-19
• 27 Brekenfeld C, Goebell E, Schmidt H. et al. 'Drip-and-drive': shipping the neurointerventionalist to provide mechanical thrombectomy in primary stroke centers. J Neurointerv Surg 2018; 10: 932-936
• 28 Seker F, Mohlenbruch MA, Nagel S. et al. Clinical results of a new concept of neurothrombectomy coverage at a remote hospital-“drive the doctor“. Int J Stroke 2018; 13: 696-699
• 29 Osanai T, Ito Y, Ushikoshi S. et al. Efficacy of 'drive and retrieve' as a cooperative method for prompt endovascular treatment for acute ischemic stroke. J Neurointerv Surg 2019;
• 30 Wei D, Oxley TJ, Nistal DA. et al. Mobile interventional stroke teams lead to faster treatment times for thrombectomy in large vessel occlusion. Stroke 2017; 48: 3295-3300
• 31 Ernst M, Psychogios MN, Schlemm E. et al. Modeling the optimal transportation for acute stroke treatment : impact of diurnal variations in traffic rate. Clin Neuroradiol 2020;
• 32 Ernst M, Schlemm E, Holodinsky JK. et al. Modeling the optimal transportation for acute stroke treatment: the impact of the drip-and-drive paradigm. Stroke 2020; 51: 275-281
• 33 Nogueira RG, Tsivgoulis G. Large vessel occlusion strokes after the DIRECT-MT and SKIP Trials: Is the alteplase syringe half empty or half full?. Stroke 2020; 51: 3182-3186
• 34 Gamba M, Gilberti N, Premi E. et al. Intravenous fibrinolysis plus endovascular thrombectomy versus direct endovascular thrombectomy for anterior circulation acute ischemic stroke: clinical and infarct volume results. BMC Neurol 2019; 19: 103
• 35 Gariel F, Lapergue B, Bourcier R. et al. Mechanical thrombectomy outcomes with or without intravenous thrombolysis. Stroke 2018; 49: 2383-2390
• 36 Kaesmacher J, Mordasini P, Arnold M. et al. Direct mechanical thrombectomy in tPA-ineligible and -eligible patients versus the bridging approach: a meta-analysis. J Neurointerv Surg 2019; 11: 20-27
• 37 Pan X, Liu G, Wu B. et al. Comparative efficacy and safety of bridging strategies with direct mechanical thrombectomy in large vessel occlusion: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e14956
• 38 Yang P, Zhang Y, Zhang L. et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. N Engl J Med 2020; 382: 1981-1993
• 39 Suzuki K, Kimura K, Takeuchi M. et al. The randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion (SKIP study). International Stroke Conference 2020; 2020
• 40 Schonewille WJ, Wijman CA, Michel P. et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol 2009; 8: 724-730
• 41 Shu L, Salehi Ravesh M, Jansen O. et al. Stent retriever thrombectomy potentially increases the recanalization rate, improves clinical outcome, and decreases mortality in acute basilar occlusion: a systematic review and meta-analysis. Cerebrovasc Dis Extra 2019; 9: 46-56
• 42 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378: 2191-2201
• 43 Diener HC, Sacco RL, Easton JD. et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380: 1906-1917
• 44 Healey JS, Gladstone DJ, Swaminathan B. et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 2019; 76: 764-773
• 45 Diener H, Grau A, Baldus S. Cryptogenic stroke and patent foramen ovale. Guidelines of the German Society of Neurology, the German Stroke Society and the German Society of Cardiology. Neurological Research and Practice 2019;
• 46 Häusler K, Neugebauer H. Closure of patent foramen ovale after ischemic stroke. Dtsch Med Wochenschr 2019; 144: 1561-1569
• 47 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;
• 48 Häusler KG, Gröschel K, Köhrmann M. et al. Positionspapier zur Detektion von Vorhofflimmern nach ischämischem Schlaganfall. Aktuelle Neurol 2018; 45: 93-106
• 49 Schnabel RB, Haeusler KG, Healey JS. et al. Searching for atrial fibrillation poststroke: A white paper of the AF-SCREEN international collaboration. Circulation 2019; 140: 1834-1850
• 50 Camen S, Haeusler KG, Schnabel RB. Cardiac imaging after ischemic stroke. Herz 2019; 44: 296-303
• 51 Camen S, Haeusler KG, Schnabel RB. Cardiac imaging after ischemic stroke or transient ischemic attack. Curr Neurol Neurosci Rep 2020; 20: 36
• 52 Steffel J, Verhamme P, Potpara TS. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20: 1231-1242
• 53 Häusler KG. Verlängertes EKG-Monitoring nach ischämischem Schlaganfall. Klinikarzt 2018; 47: 123-127
• 54 Nabavi DG, Koennecke HC, Ossenbrink M. et al. Zertifizierungskriterien für Stroke-Units in Deutschland. Update 2018. Nervenarzt 2019; 90: 335-342
• 55 Uphaus T, Weber-Kruger M, Grond M. et al. Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. Neurology 2019; 92: e115-e124
• 56 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;
• 57 Kernan WN, Ovbiagele B, Black HR. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236
• 58 Haeusler KG, Kirchhof P, Heuschmann PU. et al. Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. American Heart Journal 2016; 172: 19-25
• 59 Groschel S, Lange B, Wasser K. et al. Software-based analysis of 1-hour Holter ECG to select for prolonged ECG monitoring after stroke. Ann Clin Transl Neurol 2020;
• 60 Groschel S, Lange B, Grond M. et al. Automatic Holter electrocardiogram analysis in ischaemic stroke patients to detect paroxysmal atrial fibrillation: ready to replace physicians?. Eur J Neurol 2020; 27: 1272-1278
• 61 Kirchhof P, Camm AJ, Goette A. et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383: 1305-1316
• 62 Wasser K, Weber-Kruger M, Jurries F. et al. The cardiac diagnostic work-up in stroke patients-A subanalysis of the Find-AFRANDOMISED trial. PLoS One 2019; 14: e0216530
• 63 Häusler K, Endres M, Doehner W. Bedeutung der Herzinsuffizienz für Prävention, Therapie und Prognose des ischämischen Schlaganfalls. Aktuelle Neurol 2017; 44: 267-271
• 64 Diener H, Grau AJ, Baldus S. et al. Kryptogener Schlaganfall und offenes Foramen ovale: S2e Leitlinie der DGN, DGK und DSG. Nervenarzt 2018; 89: 1143-1153
• 65 Haeusler KG, Wollboldt C, Bentheim LZ. et al. Feasibility and diagnostic value of cardiovascular magnetic resonance imaging after acute ischemic stroke of undetermined origin. Stroke 2017; 48: 1241-1247
• 66 Charidimou A, Boulouis G, Gurol ME. et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain 2017; 140: 1829-1850
• 67 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701
• 68 Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiat 2014; 85: 660-667
• 69 Biffi A, Anderson CD, Battey TW. et al. Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. JAMA 2015; 314: 904-912
• 70 Hemphill 3rd JC, Greenberg SM, Anderson CS. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032-2060
• 71 Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. Cerebrovasc Dis 2011; 32: 528-534
• 72 Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston Criteria. Stroke 2018; 49: 491-497
• 73 Boyle PA, Yu L, Nag S. et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 2015; 85: 1930-1936
• 74 Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007; 130: 1988-2003
• 75 Charidimou A, Imaizumi T, Moulin S. et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis. Neurology 2017; 89: 820-829
• 76 Biffi A, Urday S, Kubiszewski P. et al. Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage. Stroke 2020; 51: 2153-2160
• 77 Sembill JA, Kuramatsu JB, Schwab S. et al. Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage. Neurological Research and Practice 2019; 1: 12
• 78 Murthy SB, Gupta A, Merkler AE. et al. restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke 2017; 48: 1594-1600
• 79 Kuramatsu JB, Gerner ST, Schellinger PD. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836
• 80 Biffi A, Kuramatsu JB, Leasure A. et al. Oral Anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol 2017; 82: 755-765
• 81 Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009; 373: 1632-1644
• 82 Delcourt C, Huang Y, Arima H. et al. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology 2012; 79: 314-319
• 83 Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation 2008; 118: 176-187
• 84 Xiong L, Liu X, Shang T. et al. Impaired cerebral autoregulation: measurement and application to stroke. J Neurol Neurosurg Psychiatry 2017; 88: 520-531
• 85 Qureshi AI. et al. Antihypertensive treatment of acute cerebral hemorrhage i. Antihypertensive treatment of acute cerebral hemorrhage. . Crit Care Med 2010; 38: 637-648
• 86 Anderson CS, Heeley E, Huang Y. et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-2365
• 87 Qureshi AI, Palesch YY, Barsan WG. et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375: 1033-1043
• 88 Sembill JA, Huttner HB, Kuramatsu JB. Impact of recent studies for the treatment of intracerebral hemorrhage. Curr Neurol Neurosci Rep 2018; 18: 71
• 89 Boulouis G, Morotti A, Goldstein JN. et al. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry 2017; 88: 339-345
• 90 Moullaali TJ, Wang X, Martin RH. et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol 2019; 18: 857-864
• 91 Diener HC, Connolly SJ, Ezekowitz MD. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163
• 92 Hankey GJ, Patel MR, Stevens SR. et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
• 93 Easton JD, Lopes RD, Bahit MC. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511
• 94 Rost NS, Giugliano RP, Ruff CT. et al. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke 2016; 47: 2075-2082
• 95 Xian Y, Xu H, O'Brien EC. et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol 2019;
• 96 Paschke LM, Klimke K, Altiner A. et al. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. BMC Med 2020; 18: 254
• 97 Coleman CI, Briere JB, Fauchier L. et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy 2019; 7: 1574541
• 98 Tepper PG, Mardekian J, Masseria C. et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One 2018; 13: e0205989
• 99 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
• 100 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
• 101 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
• 102 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
• 103 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;
• 104 Stoll S, Macha K, Marsch A. et al. Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation. J Neurol 2020;
• 105 Purrucker JC, Hölscher K, Kollmer J. et al. Etiology of ischemic strokes of patients with atrial fibrillation and therapy with anticoagulants. J Clin Med 2020; 9: 2938-2911
• 106 Steinberg BA, Shrader P, Pieper K. et al. Frequency and outcomes of reduced dose non-vitamin k antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 2018; 7
• 107 Ozaki AF, Choi AS, Le QT. et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2020; 13: e005969
• 108 Seiffge DJ, De Marchis GM, Koga M. et al. Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 2020;
• 109 Seiffge DJ, Paciaroni M, Wilson D. et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol 2019; 85: 823-834
• 110 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2017; 38: 2137-2149
• 111 Schiele F, van Ryn J, Canada K. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562
• 112 Kermer P, Eschenfelder CC, Diener HC. et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases. Int J Stroke 2020; 15: 609-618
• 113 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451
• 114 Christensen H, Cordonnier C, Korv J. et al. European Stroke Organisation Guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J 2019; 4: 294-306
• 115 Coutinho JM, Zuurbier SM, Bousser MG. et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: The TO-ACT randomized clinical trial. JAMA Neurol 2020;
• 116 Ferro JM, Coutinho JM, Dentali F. et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019; 76: 1457-1465